DGTR tracker

DGTR recommends anti-dumping duty on Bromo OTBN from China

DGTR published its final findings in Case No. AD(OI) - 20/2025 on June 24, 2026. DGTR recommends five-year anti-dumping duties of USD 5,089 to USD 6,305 per MT on Bromo OTBN, a sartan API intermediate, from China. It covers 4-(Bromomethyl)-2'-cyanobiphenyl, also known as Bromo OTBN from China.

Case No. AD(OI) - 20/2025 · Final findings · June 24, 2026

IndusDesk ·

The Directorate General of Trade Remedies (DGTR) has issued final findings, dated June 24, 2026 (Case No. AD(OI) - 20/2025), in the anti-dumping investigation concerning imports of 4-(Bromomethyl)-2'-cyanobiphenyl, known as Bromo OTBN, originating in or exported from China. The investigation was initiated on June 30, 2025 on an application by M/s Neogen Chemicals Limited, which DGTR found to account for a major proportion of Indian production.

Bromo OTBN is an intermediate used in making sartan-class active pharmaceutical ingredients such as Valsartan, Irbesartan and Telmisartan. The period of investigation was January to December 2024, with injury examined from April 2021. Five Chinese producers and exporters responded, and DGTR determined individual margins for three producers.

DGTR found dumping margins of 55-65% to 60-70% for the three cooperating producers and 80-90% for all others. Imports from China rose to 538 MT in the period of investigation and held 64% of Indian demand. Although the imports were not undercutting the domestic industry's prices, DGTR found that their landed value stayed materially below the domestic industry's cost of production, and that the domestic industry incurred losses throughout the injury period. It found a causal link between the dumped imports and the injury.

DGTR recommends a duty for five years of USD 5,089 per MT for Yancheng City DongGang Pharmaceutical Development Co., Ltd, USD 5,500 per MT for Linhai Huanan Chemical Co., Ltd., USD 5,440 per MT for Zhejiang Tianyu Pharmaceutical Co., Ltd., and USD 6,305 per MT for all other producers and for goods of other origin exported from China. The individual rates apply only against a commercial invoice carrying a declaration, signed by an official of the invoicing entity, that names the producer. The five-year period would run from the date of the notification to be issued by the Central Government.

Measure
Anti-dumping
Stage
Final findings
Case number
Case No. AD(OI) - 20/2025
File number
F. No. 6/23/2025-DGTR
Dated
June 24, 2026
Published in the Gazette
June 24, 2026
Put online
July 2, 2026
Gazette ID
CG-DL-E-02072026-273965
Product
4-(Bromomethyl)-2'-cyanobiphenyl, also known as Bromo OTBN
What it covers
A cream or off-white powder used as an intermediate in making sartan-class pharmaceutical APIs, mainly Valsartan, Irbesartan and Telmisartan. The scope remains as defined in the initiation notification, and no PCN methodology was adopted.
Customs codes
29269000, 29339990, 29332990, 29420090, 29152990
Countries
China
Applicant
M/s Neogen Chemicals Limited
Period of investigation
January 2024 – December 2024 (12 Months)
Injury period
April 2021 to March 2022, April 2022 to March 2023, April 2023 to March 2024 and the POI
Findings
  • Normal value for China was constructed on the basis of the domestic industry's optimized cost of production with reasonable selling, general and administrative expenses and profit, as no information or evidence was provided for the first two methods under paragraph 7 of Annexure I.
  • The dumping margin is 55-65% for Yancheng City DongGang Pharmaceutical Development Co., Ltd, 60-70% for Linhai Huanan Chemical Co., Ltd. and for Zhejiang Tianyu Pharmaceutical Co., Ltd., and 80-90% for all others.
  • The injury margin is 50-60% for Yancheng City Donggang Pharmaceutical Development Co., Ltd. and Zhejiang Tianyu Pharmaceutical Co., Ltd., 60-70% for Linhai Huanan Chemical Co., Ltd., and 80-90% for all others.
  • Imports from China were 456 MT in 2021-22, 426 MT in 2022-23, 501 MT in 2023-24 and 538 MT in the POI, with no imports from other countries; in the POI they held 64% of Indian demand against 20% for the domestic industry.
  • Price undercutting is negative in the POI, but the landed value of imports remained materially below the domestic industry's cost of production throughout the injury period, which the Authority found caused price suppression and depression.
  • The domestic industry's production, capacity utilization and sales rose in the POI, but it incurred losses, negative cash profits and negative return on capital employed throughout the injury period, and its average inventory increased significantly.
  • The Authority found a causal link between the dumped imports and the material injury, and that other known factors do not negate it.
  • The Authority estimated the impact of the duty on patients at 0.62% of the MRP of Losartan 50 mg tablets (Rs. 0.93 on a monthly pack of 30 tablets) and found imposition of the duty consistent with the wider public interest.
Recommendation
DGTR recommends anti-dumping duty, equal to the lesser of the dumping margin and the injury margin, on imports of the subject goods originating in or exported from China, for five years from the date of the notification to be issued by the Central Government, ranging from USD 5,089 to USD 6,305 per MT.
Duty expressed as
USD per MT
For how long
five (5) years from the date of notification to be issued in this regard by the Central Government
What happens next
The recommended duty would apply for five years from the date of the notification to be issued in this regard by the Central Government. An appeal against the final findings lies before the Customs, Excise and Service Tax Appellate Tribunal.

The duty table

CountryProducerDuty
China PRYancheng City DongGang Pharmaceutical Development Co., Ltd5,089 USD per MT
China PRLinhai Huanan Chemical Co., Ltd.5,500 USD per MT
China PRZhejiang Tianyu Pharmaceutical Co., Ltd.5,440 USD per MT
China PRAny producer other than S No. 1 to 36,305 USD per MT
Any country other than China PR (country of origin), exported from China PRAny6,305 USD per MT

The notification (PDF, 1.4 MB)

Gazette of India, CG-DL-E-02072026-273965, published June 24, 2026.

Checked against the official copy on October 20, 2026.